RCM Technologies, Inc. — Form 10-K Summary
Period note: The request identifies “2021 Q4,” but the filing is the annual report for the fiscal year ended December 31, 2022, compared primarily with the 52-week fiscal year ended January 1, 2022. The filing does not provide a clear standalone fourth-quarter income statement.
Business context and reporting period
RCM provides specialty health care staffing, engineering, life sciences and information technology services through three segments: Specialty Health Care, Engineering, and Life Sciences and Information Technology (LS&IT). Fiscal 2022 revenue mix was 56.0%, 30.2%, and 13.8%, respectively. Approximately 4.4% of revenue came from outside the United States.
Financial performance and liquidity
Amounts below are in millions of dollars unless noted; fiscal years ended December 31, 2022 and January 1, 2022, respectively.
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $284.7 | $203.9 |
| Gross profit / margin | $82.9 / 29.1% | $53.1 / 26.1% |
| Operating income / margin | $28.8 / 10.1% | $14.1 / 6.9% |
| Net income | $20.9 | $11.0 |
| Diluted earnings per share | $2.00 | $0.95 |
| Cash from operating activities | $28.3 | $0.9 |
| Cash used in investing activities | $4.8 | Cash provided: $6.3 |
| Cash used in financing activities | $23.1 | $7.6 |
- Adjusted EBITDA, a non-GAAP measure, was $29.5 million, versus $11.1 million. The company cautions that this measure is not a substitute for GAAP results or cash flow.
- At year-end, current assets were $59.0 million and current liabilities $40.4 million, a working-capital surplus of $18.6 million. Cash was $0.3 million; net accounts receivable was $50.8 million.
- Revolver borrowings were $8.8 million, with $34.3 million of additional availability and $1.9 million in letters of credit. The $45 million facility was scheduled to expire August 8, 2023. The company reported covenant compliance at year-end.
- Operating cash flow rose substantially, while financing cash use included $17.6 million of share repurchases. Investing cash use included $4.2 million for the TalentHerder acquisition.
Material changes versus the prior comparable year
- Revenue increased 39.6% ($80.8 million). Specialty Health Care grew $60.9 million, Engineering $19.8 million, and LS&IT $0.1 million.
- Specialty Health Care revenue grew 61.9% to $159.4 million as schools reopened and demand for health care professionals remained high. Segment operating income rose to $19.8 million from $5.5 million.
- Engineering revenue rose 29.9% to $85.9 million, led by aerospace and industrial processing work. Operating income fell to $4.3 million from $5.4 million, in part because the prior year included larger divestiture and contingent-consideration gains.
- LS&IT revenue was essentially flat at $39.3 million, while operating income increased to $4.7 million from $3.3 million, supported by improved gross margin.
- Company gross margin improved to 29.1% from 26.1%; SG&A increased in dollars to $53.4 million but declined as a share of revenue to 18.8% from 20.6%.
- The effective tax rate increased to 26.7% from 21.0%. Management described the prior-year rate as abnormally low and estimated its normalized rate at 27.5%.
Outlook, commentary, risks and unusual items
- Outlook: No specific revenue, earnings, or margin guidance was provided. Management said it believed the company could meet liquidity needs for at least 12 months and saw potential for Specialty Health Care growth, subject to seasonality. It expects demand in health care to remain above pre-pandemic levels, while noting COVID-related revenue had declined as the pandemic shifted toward an endemic.
- Concentration and seasonality: Two customers each generated more than 10% of 2022 revenue (13.2% and 12.7%); the five largest generated 43.0%. School closures affect Specialty Health Care activity, and client budget cycles, holidays and weather can affect other segments.
- Controls warning: Management and the auditor concluded internal control over financial reporting was ineffective because of material weaknesses in SAP and related IT general controls, including segregation of duties, administrator access, change management and user access. The auditor issued an adverse opinion on internal controls but an unqualified opinion on the financial statements. Management said the weakness had not caused a reported misstatement and remediation was in progress; timing of full remediation remains uncertain.
- Legal contingency: The company accrued $2.9 million for asserted claims. A client dispute concerning an industrial processing system includes a $0.5 million reserve; the company believes potential damages may be contractually capped at $3.3 million and insured, but gives no assurance on either limitation or coverage.
- Acquisition and other items: RCM acquired TalentHerder for stated consideration of $6.7 million, including $4.2 million cash, $0.6 million stock and $1.9 million estimated contingent consideration. The purchase-price allocation was preliminary. The company also reported a $0.2 million gain related to escrow proceeds from its 2021 Canadian Power Systems sale.
- Other risks: Management cites labor availability and costs, customer concentration and collection risk, competition and pricing pressure, economic sensitivity, variable borrowing costs, foreign exchange exposure, cyber and privacy risks, and potential effects of the Russia-Ukraine conflict on Serbian operations. The company does not hedge foreign-currency exposure.
- Capital allocation: No dividends were declared in 2021 or 2022, and the company had no current dividend plans. A new share repurchase authorization allowed up to $25 million; $10.2 million remained available at year-end. The company reported purchasing an additional 437,486 shares for $4.4 million through March 15, 2023.
Most important facts for investors to verify
- Confirm the intended period: this filing reports fiscal 2022, not fiscal 2021 Q4, and does not clearly provide standalone quarterly results.
- Track remediation and independent testing of the material weaknesses in financial-reporting IT controls.
- Assess whether 2022’s Specialty Health Care growth and improved margins are sustainable as COVID-related demand recedes and school-related seasonality resumes.
- Monitor customer concentration, receivable collection, and the company’s ability to fund operations and repurchases as interest rates rise and the revolver approaches its stated expiration.
- Review outcomes and reserve adequacy for the industrial processing dispute and other claims, and the final TalentHerder purchase-price allocation and contingent payments.
Data note: The filing’s MD&A and debt footnote report different fourth-quarter weighted-average borrowing rates, 5.6% and 5.2%, respectively; verify the applicable figure in the filed statements or company disclosures.